ReviewCurrent diabetes reports2013
Hyperglycemia and vascular metabolic memory: truth or fiction?
Review in Current diabetes reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The efficacy and safety of dachaihu decoction in the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Pooled it
- Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes.Diabetes care · 2022Trial
- ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial.Diabetologia · 2017Trial
- CircPBX1 ameliorates metabolic memory-associated erectile dysfunction via miR-195-5p/YAP1-mediated angiogenesis in diabetic rats.Communications biology · 2026Article
- Diabetes Mellitus and Associated Vascular Disease: Pathogenesis, Complications, and Evolving Treatments.Advances in therapy · 2025Review
- Glycemic Comparison Index (GCI): a retrospective analysis of its prognostic value in ICU patients with AMI and diabetes.BMC endocrine disorders · 2025Article
- Subcellular mass spectrometric detection unveils hyperglycemic memory in the diabetic heart.Journal of diabetes · 2024Article
- Metabolomics analysis of serum and urine in type 1 diabetes patients with different time in range derived from continuous glucose monitoring.Diabetology & metabolic syndrome · 2024Article
- Positive feedback loop of miR-320 and CD36 regulates the hyperglycemic memory-induced diabetic diastolic cardiac dysfunction.Molecular therapy. Nucleic acids · 2023Article
- The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases.International journal of molecular sciences · 2022Review
- Review
- Hyperglycemic memory in diabetic cardiomyopathy.Frontiers of medicine · 2022Review
- Does epigenetics have a role in age related macular degeneration and diabetic retinopathy?Genes & diseases · 2021Review
- To Assess Liraglutide's Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- The Legacy Effect in the Prevention of Cardiovascular Disease.Nutrients · 2020Review
- Evidence for a More Disrupted Immune-Endocrine Relation and Cortisol Immunologic Influences in the Context of Tuberculosis and Type 2 Diabetes Comorbidity.Frontiers in endocrinology · 2020Article
- Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up.The New England journal of medicine · 2019Observational
- Epigenetic Risk Profile of Diabetic Kidney Disease in High-Risk Populations.Current diabetes reports · 2019Review
- Vascular Oxidative Stress: Impact and Therapeutic Approaches.Frontiers in physiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prevention of long-term complications remains the main challenge in the treatment of diabetes. A strong relationship between glucose control and development of complications is apparent in all epidemiologic studies. Yet, intervention trials have yielded questionable results, particularly when intensive treatment was introduced in patients with long-standing diabetes. It has been postulated that in these subjects, prior exposure to chronic hyperglycemia may have generated a negative "metabolic memory," preventing full exertion of the beneficial effects of any subsequent improvement of glucose control. This phenomenon has been replicated in animal models and it recognizes a molecular basis in the role of oxidative stress, advanced glycation processes, and epigenetic mechanisms accounting for self-perpetuating modifications of gene expression. Conversely, early intervention in both type 1 and type 2 diabetes has proven that good glycemic control reduces the risk of development and progression of complications with a beneficial effect that extends well beyond the duration of near-normoglycemia. This has brought up the concept of "metabolic legacy," an advantage handed down by early and effective implementation of treatments designed to reduce blood glucose levels as safely as possible along with multifactorial intervention of all cardiovascular risk factors. The evidence, nature, and clinical implication of these concepts are reviewed.
Indexed as
Identifiers
23456482What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.